Roche’s House Advantage: Does Having It All Under One Roof Make A Difference?

10 Jun 2013

• By Mary Jo Laffler and Shirley Haley

The size of Roche’s pipeline and in-house diagnostics business are key advantages in oncology, top execs told the firm’s analyst meeting at ASCO. Roche’s oncology strategy includes replicating its HER2 success in hematology, targeting new pathways, entering immunotherapy and going all-in on antibody-drug conjugates.

Roche/Genentech Inc. execs believe that the advantages of having the breadth of activities across the company and the depth of its pipeline provide an in-house edge that is part of the key to its success in oncology.

“I do think it gives us a tremendous competitive advantage to have as many products within one company as possible,”...